Dr. Andrew M. Evens, DO, MS
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Midwestern University, Chicago College of Osteopathic Med (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 108
Licensed in Illinois since 1998, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Midwestern University, Chicago College of Osteopathic Med
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
NJ license 25MB10237400 · IL license 036-098507 (first issued 1998; not renewed) -
Hematology & Oncology Physician
MA license 246238 -
Medical Oncology Physician
NJ license 25MB10237400
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Robert Wood Johnson University Hospital New Brunswick, NJ
- Monmouth Medical Center-Southern Campus Lakewood, NJ
Medical groups
- Rutgers Health-Rwj Scleroderma Program (391 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 108
- Services billed
- 383
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 193 | 79 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 108 | 46 |
| Established patient office or other outpatient visit, 30-39 minutes | 31 | 25 |
| New patient office or other outpatient visit, 60-74 minutes | 27 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Calquence (acalabrutinib maleate) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $5,513 in total to this clinician.
| Genentech USA, Inc. | $5,463 |
|---|---|
| Pfizer Inc. | $50.19 |
| Consulting Fee | $5,330 |
|---|---|
| Food and Beverage | $183 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Jul 28, 2025 | Consulting Fee Polivy; Columvi; Lunsumio · BioOncology | $2,870 |
| Genentech USA, Inc. Dec 4, 2025 | Consulting Fee Polivy · BioOncology | $2,460 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $457,050 in research payments for these studies, mostly to the institutions running them.
- A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Ipsen Biopharmaceuticals, Inc · Active, not recruiting · NCT05551936
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.